MA54541A - Formes cristallines et salines d'un composé organique et compositions pharmaceutiques associées - Google Patents
Formes cristallines et salines d'un composé organique et compositions pharmaceutiques associéesInfo
- Publication number
- MA54541A MA54541A MA054541A MA54541A MA54541A MA 54541 A MA54541 A MA 54541A MA 054541 A MA054541 A MA 054541A MA 54541 A MA54541 A MA 54541A MA 54541 A MA54541 A MA 54541A
- Authority
- MA
- Morocco
- Prior art keywords
- crystalline
- pharmaceutical compositions
- organic compound
- salt forms
- related pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862784083P | 2018-12-21 | 2018-12-21 | |
| US201962791571P | 2019-01-11 | 2019-01-11 | |
| US201962882712P | 2019-08-05 | 2019-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54541A true MA54541A (fr) | 2022-03-09 |
Family
ID=69185721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054541A MA54541A (fr) | 2018-12-21 | 2019-12-20 | Formes cristallines et salines d'un composé organique et compositions pharmaceutiques associées |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US12297179B2 (fr) |
| EP (1) | EP3898597A1 (fr) |
| JP (3) | JP2022515239A (fr) |
| KR (1) | KR20220035022A (fr) |
| CN (1) | CN113508108B (fr) |
| AU (1) | AU2019403396B2 (fr) |
| BR (1) | BR112021012305A2 (fr) |
| CL (1) | CL2021001640A1 (fr) |
| CO (1) | CO2021009309A2 (fr) |
| CR (1) | CR20210394A (fr) |
| GE (2) | GEP20247683B (fr) |
| IL (1) | IL284218B2 (fr) |
| JO (1) | JOP20210147A1 (fr) |
| MA (1) | MA54541A (fr) |
| MX (1) | MX2021007536A (fr) |
| NI (1) | NI202100055A (fr) |
| PE (2) | PE20260309A1 (fr) |
| PH (1) | PH12021551495A1 (fr) |
| SG (1) | SG11202106526UA (fr) |
| TW (1) | TWI875727B (fr) |
| UA (1) | UA130491C2 (fr) |
| WO (1) | WO2020132471A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3060390A1 (fr) | 2017-04-24 | 2018-11-01 | Aurigene Discovery Technologies Limited | Methodes d'utilisation de derives de benzotriazole trisubstitues en tant qu'inhibiteurs de dihydroorotate oxygenase |
| CA3091792A1 (fr) | 2018-02-20 | 2019-08-29 | Agios Pharmaceuticals, Inc. | Procedes d'utilisation de derives de benzotriazole trisubstitues |
| KR20230078997A (ko) | 2020-08-27 | 2023-06-05 | 르 라보레또레 쎄르비에르 | 병용 암 요법에서의 dhodh 저해제 화합물의 용도 |
| WO2025227007A1 (fr) * | 2024-04-26 | 2025-10-30 | Ohio State Innovation Foundation | Méthodes et compositions pour inhiber la dihydroorotate déshydrogénase |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7622000A (en) * | 1999-10-01 | 2001-05-10 | Institute Of Molecular And Cell Biology | Compounds for the treatment of viral-mediated diseases |
| JP2007015952A (ja) * | 2005-07-06 | 2007-01-25 | Shionogi & Co Ltd | ナフタレン誘導体 |
| MX2010010300A (es) | 2008-03-19 | 2010-10-26 | Osi Pharm Inc | Formas de sal de inhibidores del objetivo de rapamicina en mamiferos. |
| EP2230232A1 (fr) | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Sels adjuvants de trométhamine dotés de dérivés d'acide azabiphénylaminobenzoïque en tant qu'inhibiteurs de la DHOD |
| EP2228367A1 (fr) | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Sels adjuvants d'amines contenant des groupes hydroxyle et/ou carbonyle avec des dérivés d'acides aminonicotiques en tant qu'inhibiteurs de la DHODH |
| JP5808818B2 (ja) * | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| US9360932B1 (en) | 2012-08-29 | 2016-06-07 | Intellect Motion Llc. | Systems and methods for virtually displaying real movements of objects in a 3D-space by means of 2D-video capture |
| CN103965133B (zh) * | 2013-01-31 | 2018-11-30 | 华东理工大学 | 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途 |
| ES2694829T3 (es) | 2013-02-25 | 2018-12-27 | Aurigene Discovery Technologies Limited | Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa |
| MX2018008169A (es) | 2015-12-30 | 2019-02-20 | Agios Pharmaceuticals Inc | Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante. |
| JOP20190094A1 (ar) | 2016-10-27 | 2019-04-25 | Broad Inst Inc | مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh) |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| CA3091792A1 (fr) | 2018-02-20 | 2019-08-29 | Agios Pharmaceuticals, Inc. | Procedes d'utilisation de derives de benzotriazole trisubstitues |
| US20230285364A1 (en) * | 2020-06-24 | 2023-09-14 | Servier Pharmaceuticals Llc | Use of a dhodh inhibitor compound in combination cancer therapy |
| KR20230078997A (ko) * | 2020-08-27 | 2023-06-05 | 르 라보레또레 쎄르비에르 | 병용 암 요법에서의 dhodh 저해제 화합물의 용도 |
-
2019
- 2019-12-20 BR BR112021012305-9A patent/BR112021012305A2/pt unknown
- 2019-12-20 PE PE2025003120A patent/PE20260309A1/es unknown
- 2019-12-20 KR KR1020217022945A patent/KR20220035022A/ko active Pending
- 2019-12-20 CR CR20210394A patent/CR20210394A/es unknown
- 2019-12-20 TW TW108147117A patent/TWI875727B/zh active
- 2019-12-20 WO PCT/US2019/067897 patent/WO2020132471A1/fr not_active Ceased
- 2019-12-20 MA MA054541A patent/MA54541A/fr unknown
- 2019-12-20 IL IL284218A patent/IL284218B2/en unknown
- 2019-12-20 CN CN201980091991.XA patent/CN113508108B/zh active Active
- 2019-12-20 PE PE2021001052A patent/PE20212197A1/es unknown
- 2019-12-20 EP EP19839747.3A patent/EP3898597A1/fr active Pending
- 2019-12-20 JO JOP/2021/0147A patent/JOP20210147A1/ar unknown
- 2019-12-20 JP JP2021536323A patent/JP2022515239A/ja active Pending
- 2019-12-20 MX MX2021007536A patent/MX2021007536A/es unknown
- 2019-12-20 UA UAA202104251A patent/UA130491C2/uk unknown
- 2019-12-20 AU AU2019403396A patent/AU2019403396B2/en active Active
- 2019-12-20 GE GEAP201915700A patent/GEP20247683B/en unknown
- 2019-12-20 GE GEAP202415700A patent/GEAP202415700A/en unknown
- 2019-12-20 US US17/416,910 patent/US12297179B2/en active Active
- 2019-12-20 SG SG11202106526UA patent/SG11202106526UA/en unknown
-
2020
- 2020-01-09 PH PH1/2021/551495A patent/PH12021551495A1/en unknown
-
2021
- 2021-06-18 CL CL2021001640A patent/CL2021001640A1/es unknown
- 2021-06-21 NI NI202100055A patent/NI202100055A/es unknown
- 2021-07-15 CO CONC2021/0009309A patent/CO2021009309A2/es unknown
-
2024
- 2024-08-07 JP JP2024131002A patent/JP7749080B2/ja active Active
-
2025
- 2025-05-07 US US19/201,581 patent/US20250270175A1/en active Pending
- 2025-09-22 JP JP2025156833A patent/JP2026001058A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3924352A4 (fr) | Formes cristallines d'un inhibiteur rsk | |
| MA54526A (fr) | NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta | |
| EP3619208C0 (fr) | Formes cristallines d'un composé inhibiteur de jak | |
| EP3897660A4 (fr) | Nouvelles formes cristallines d'un composé de nrtti | |
| EP3870181A4 (fr) | Formes cristallines d'un inhibiteur d'alk2 | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| IL270780A (en) | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use | |
| EP3373934A4 (fr) | Forme cristalline d'un composé de quinoléine substitué et compositions pharmaceutiques en contenant | |
| CL2008002241A1 (es) | Compuestos derivados de (hetero)aril-metilen-n-cicloalquil carboxamida condensados de 6 elementos con n-sustituido; composicion funguicida que comprende uno de dichos compuestos; y metodo para el control hongos fitopatogenos de cultivos agricolas. | |
| EP4263488A4 (fr) | Formes solides d'un composé | |
| MX388175B (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| IL284218A (en) | Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof | |
| CU20190029A7 (es) | Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos | |
| MX394624B (es) | Inhibidores selectivos hdac6, métodos de preparación y aplicación de los mismos. | |
| EP3808747A4 (fr) | Composé d'imidazopyridinone | |
| EP3870179A4 (fr) | Inhibition d'usp7 | |
| CO2020011860A2 (es) | Compuestos de 4–metildihidropirimidinona y su uso farmacéutico | |
| EP4015002A4 (fr) | Composition pharmaceutique orale contenant un composé hétérocyclique | |
| IL285763A (en) | Solid polymorphs of a flna-binding compound and its hydrochloride salts | |
| MA53162A (fr) | Sel de xinafoate d'un composé inhibiteur de jak | |
| EP3470410A4 (fr) | Forme cristalline du composé supprimant l'activité de la protéine kinase et application associée | |
| MX2022006104A (es) | Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma. | |
| EA201990766A1 (ru) | Индазольные соединения для применения при повреждениях сухожилий и/или связок | |
| EP3849964A4 (fr) | Formes cristallines d'un composé de quinazole et ses sels de chlorhydrate | |
| EP3672972A4 (fr) | Sels et formes cristallines d'un composé |